Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

75.25USD
15 Feb 2019
Change (% chg)

$1.28 (+1.73%)
Prev Close
$73.97
Open
$74.56
Day's High
$75.40
Day's Low
$74.33
Volume
8,083,239
Avg. Vol
7,208,142
52-wk High
$75.40
52-wk Low
$56.81

Chart for

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.12
Market Cap(Mil.): $132,164.09
Shares Outstanding(Mil.): 1,756.33
Dividend: 0.32
Yield (%): 1.70

Financials

  ABT Industry Sector
P/E (TTM): 53.89 33.62 36.24
EPS (TTM): 1.40 -- --
ROI: -- 12.54 12.71
ROE: -- 14.82 13.70

Abbott's Alere to resolve securities fraud case for $20 million

Alere Inc, now a unit of Abbott Laboratories Inc, has agreed to pay $20 million to resolve claims it made false and misleading statements to investors in the lead up to the announcement of a deal to sell the diagnostic testing company to Abbott.

Feb 04 2019

Abbott escapes lawsuit over recalled St. Jude defibrillators

Jan 25 - Abbott Laboratories has escaped a proposed class action lawsuit alleging its subsidiary St. Jude Medical concealed a potentially deadly battery defect in some of its cardiac defibrillators for years before finally recalling them in 2016.

Jan 25 2019

Abbott misses revenue estimates, sees lackluster first-quarter profit

Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.

Jan 23 2019

UPDATE 3-Abbott misses revenue estimates, sees lackluster first-qtr profit

Jan 23 Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.

Jan 23 2019

Abbott Labs says M&A not a high priority now

Healthcare company Abbott Laboratories will not focus on mergers and acquisitions in the near future, Chief Executive Officer Miles White said on a conference call on Wednesday.

Jan 23 2019

Abbott Labs says M&A not a high priority now

Jan 23 Healthcare company Abbott Laboratories will not focus on mergers and acquisitions in the near future, Chief Executive Officer Miles White said on a conference call on Wednesday.

Jan 23 2019

Abbott Lab's fourth-quarter revenue rises 2.3 pct

Jan 23 Abbott Laboratories posted a 2.3 percent rise in fourth-quarter revenue on Wednesday, helped by growing demand for its heart valves and glucose monitoring devices.

Jan 23 2019

Abbott resolves N.Y. claims over misleading infant-feeding surveys

Abbott Laboratories, the maker of Similac infant formula, has agreed to not falsely represent that surveys it mails new parents are for scientific research instead of marketing purposes and to accurately disclose their purpose.

Nov 09 2018

Abbott, AbbVie settle TriCor marketing case for $25 million

Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

Oct 26 2018

UPDATE 2-Abbott, AbbVie settle TriCor marketing case for $25 mln

Oct 26 Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

Oct 26 2018

Earnings vs. Estimates